Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2020
Remdesivir’s hefty price tag ignores NIH investment in its creation
22 October 2020 - Throughout the Democratic presidential primary, candidates cast a spotlight on the broken U.S. health care system ...
Posted by Michael Wonder on 19 Aug 2020
Financing drug innovation in the US: current framework and emerging challenges
19 August 2020 - The current US drug innovation financing framework rests on the notion that a defined period of marketing ...
Posted by Michael Wonder on 10 Aug 2020
Coming of age: emerging health preference research based on established scientific standards
10 August 2020 - Value in Health themed section enhances the scientific respectability and relevance of health preference research. ...
Posted by Michael Wonder on 10 Aug 2020
Australian start-ups push for bigger role in vaccine making
9 August 2020 - An Australian startup racing to develop a successful coronavirus vaccine has urged the federal government to ...
Posted by Michael Wonder on 06 Aug 2020
Italy becomes first country to require pharma to disclose public funding for R&D costs
6 August 2020 - Amid growing clamour for more transparency from the pharmaceutical industry, Italy has become the first country ...
Posted by Michael Wonder on 06 Aug 2020
The world is spending nowhere near enough on a coronavirus vaccine
6 August 2020 - Far better to spend far too much. ...
Posted by Michael Wonder on 06 May 2020
Scientific research on the coronavirus is being released in a torrent
6 May 2020 - Will that change how science is published? ...
Posted by Michael Wonder on 18 Apr 2020
Greg Hunt: Australia now leading the race for a vaccine
16 April 2020 - Australia has long punched above its weight in health and medical research — think Gardasil, cochlear and ...
Posted by Michael Wonder on 07 Apr 2020
Scientists rush to find coronavirus cure—but it still isn’t fast enough
6 April 2020 - For drug companies, there is suddenly only one priority: the coronavirus. ...
Posted by Michael Wonder on 26 Mar 2020
Preserving clinical trial integrity during the coronavirus pandemic
25 March 2020 - Randomised clinical trials provide the highest-quality evidence for identifying therapies to help people attain longer and healthier ...
Posted by Michael Wonder on 25 Mar 2020
Treating COVID-19—off-label drug use, compassionate use, and randomised clinical trials during pandemics
24 March 2020 - In the 2014 Ebola outbreak, close to 30 000 individuals developed Ebola viral disease, and numerous therapies were ...
Posted by Michael Wonder on 19 Feb 2020
FDA touts generic drug research in 2019
19 February 2020 - The US FDA on Tuesday released a report detailing the scientific research carried out and funded ...
Posted by Michael Wonder on 14 Jan 2020
Incidental imaging findings in clinical trials
13 January 2020 - Clinical trial end points are outcome measures used to assess the efficacy and safety of an ...
Posted by Michael Wonder on 06 Dec 2019
Proposed changes to research and development tax incentive will discourage investment and undermine innovation
6 December 2019 - Medicines Australia is disappointed that proposed changes to the Research and Development Tax Incentive were tabled ...
Posted by Michael Wonder on 02 Oct 2019
The real impact of drug price legislation on biopharmaceutical R&D
2 October 2019 - As outcry around drug prices rages, arguments continue to surface that limiting corporate revenues via price controls ...